Get started
Author

Zoltán Kaló

Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force
2016 · Praveen Thokala, Nancy Devlin, et al. · Value in Health · 733
PDF
Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force
2016 · Kevin Marsh, Maarten IJzerman, et al. · Value in Health · 485
PDF
Comparison of weighting methods used in multicriteria decision analysis frameworks in healthcare with focus on low- and middle-income countries
2019 · Bertalan Németh, Anett Molnár, et al. · Journal of Comparative Effectiveness Research · 149
Burden of Atopic Dermatitis in Adults and Adolescents: a Systematic Literature Review
2022 · Ahmad N. Fasseeh, Baher Elezbawy, et al. · Dermatology and Therapy · 137
PDF
Policy objective of generic medicines from the investment perspective: The case of clopidogrel
2017 · Péter Elek, András Harsányi, et al. · Health Policy · 136
Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group
2018 · Sandra Nestler-Parr, Daria Korchagina, et al. · Value in Health · 129
The Life‐Years Saved by a Deceased Organ Donor
2005 · Mark A. Schnitzler, James F. Whiting, et al. · American Journal of Transplantation · 121
Cost-Effectiveness of Organ Donation: Evaluating Investment into Donor Action and Other Donor Initiatives
2004 · James F. Whiting, Bryce Kiberd, et al. · American Journal of Transplantation · 113
PDF
The expanded criterial donor dilemma in cadaveric renal transplantation
2003 · Mark A. Schnitzler, James F. Whiting, et al. · Transplantation · 111
Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments
2004 · WK Redekop, EA Stolk, et al. · Diabetes & Metabolism · 93
Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer
2021 · András Inotai, Tamás Ágh, et al. · Cancer Treatment Reviews · 76
HTA Implementation Roadmap in Central and Eastern European Countries
2016 · Zoltán Kaló, Adrian Gheorghe, et al. · Health Economics · 75
PDF
The Cost Effectiveness of Apligraf?? Treatment of Diabetic Foot Ulcers
2003 · W Ken Redekop, Joseph McDonnell, et al. · PharmacoEconomics · 75
Implementation of Health Technology Assessment in the Middle East and North Africa: Comparison Between the Current and Preferred Status
2020 · Ahmad Fasseeh, Rita Karam, et al. · Frontiers in Pharmacology · 74
PDF
Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt
2013 · Gihan H. Elsisi, Zoltán Kaló, et al. · Value in Health Regional Issues · 72
Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries
2016 · Tamás Zelei, Mária J. Molnár, et al. · Orphanet Journal of Rare Diseases · 66
PDF
The European challenges of funding orphan medicinal products
2018 · Márta Szegedi, Tamás Zelei, et al. · Orphanet Journal of Rare Diseases · 64
PDF
Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer
2016 · A.T. Zemplényi, Z. Kaló, et al. · European Journal of Cancer Care · 62
Resource Use and Treatment Costs After Kidney Transplantation: Impact of Demographic Factors, Comorbidities, and Complications
2004 · Ernst-Günther Hagenmeyer, Bertram Häussler, et al. · Transplantation · 61
Healthcare financing in Egypt: a systematic literature review.
2022 · Ahmad Fasseeh, Baher ElEzbawy, et al. · Journal of the Egyptian Public Health Association · 60
PDF
Direct healthcare cost of schizophrenia – European overview
2018 · G. Kovács, T. Almási, et al. · European Psychiatry · 58
PDF
Need for Multicriteria Evaluation of Generic Drug Policies
2015 · Zoltán Kaló, Anke-Peggy Holtorf, et al. · Value in Health · 54
Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
2016 · Katarzyna Kolasa, Krzysztof M. Zwolinski, et al. · Orphanet Journal of Rare Diseases · 53
PDF
Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development
2010 · József Bodrogi, Zoltán Kaló · British Journal of Pharmacology · 52
PDF
Differential pricing of new pharmaceuticals in lower income European countries
2013 · Zoltán Kaló, Lieven Annemans, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 51
Works count: 389
Citation count: 5,995
H-index: 38
I10-index: 132
Year
Topic
Type